Immunization, Hib3 in Low income
Low income: Immunization, Hib3 was 70.2% in 2024. ◆ Volatile
Immunization, Hib3 in Low income, 1990–2024
Source: WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/). Measured in % of children ages 12-23 months.
Analysis
Low income recorded 70.2% for immunization, hib3 in 2024.
That represents a change of up 0.9% on the previous year and down 2.0% over ten years.
Over the whole period, immunization, hib3 in Low income peaked at 74.6% in 2019 and was at its lowest, 0.0%, in 1990.
Low income ranks 38th of 43 groups on this measure, in the bottom quarter.
The series is highly variable year to year, so single readings are best treated with caution.
Immunization, Hib3 in Low income, year by year
| Year | % of children ages 12-23 months | Change |
|---|---|---|
| 1990 | 0.0% | — |
| 1991 | 0.0% | — |
| 1992 | 0.0% | — |
| 1993 | 0.0% | — |
| 1994 | 0.0% | — |
| 1995 | 0.0% | — |
| 1996 | 0.0% | — |
| 1997 | 0.0% | — |
| 1998 | 0.4% | — |
| 1999 | 0.4% | -3.7% |
| 2000 | 0.3% | -4.9% |
| 2001 | 3.3% | +845.0% |
| 2002 | 9.0% | +174.5% |
| 2003 | 10.8% | +20.3% |
| 2004 | 13.5% | +25.7% |
| 2005 | 16.2% | +19.8% |
| 2006 | 21.2% | +30.8% |
| 2007 | 32.7% | +54.0% |
| 2008 | 44.0% | +34.7% |
| 2009 | 67.3% | +52.9% |
| 2010 | 67.3% | -0.0% |
| 2011 | 69.4% | +3.1% |
| 2012 | 69.1% | -0.5% |
| 2013 | 70.4% | +1.9% |
| 2014 | 71.6% | +1.7% |
| 2015 | 72.4% | +1.1% |
| 2016 | 73.4% | +1.4% |
| 2017 | 74.2% | +1.1% |
| 2018 | 73.9% | -0.3% |
| 2019 | 74.6% | +0.9% |
| 2020 | 71.9% | -3.6% |
| 2021 | 70.0% | -2.7% |
| 2022 | 70.6% | +0.8% |
| 2023 | 69.6% | -1.4% |
| 2024 | 70.2% | +0.9% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 1990s | 0.1% | 0.0% | 0.4% | 10 |
| 2000s | 21.8% | 0.3% | 67.3% | 10 |
| 2010s | 71.6% | 67.3% | 74.6% | 10 |
| 2020s | 70.4% | 69.6% | 71.9% | 5 |
More health data for Low income
- Population ages 40-44, female, per capita 0.0225 units per person (2025)
- Population ages 35-39, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 35-39, male, per capita 0.027 units per person (2025)
- Population ages 40-44, female, annual growth rate 3.49 % change on previous year (2025)
- Population ages 40-44, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 40-44, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 45-49, female, annual growth rate 3.59 % change on previous year (2025)
- Population ages 40-44, male, per capita 0.0218 units per person (2025)
- Population ages 35-39, male, annual growth rate 3.86 % change on previous year (2025)
- Population ages 40-44, male, annual growth rate 3.55 % change on previous year (2025)
Frequently asked questions
- What is immunization, hib3 in Low income?
- Immunization, hib3 in Low income was 70.2% in 2024, according to WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).
- What is the highest immunization, hib3 recorded in Low income?
- The highest recorded value was 74.6% in 2019.
- What is the lowest immunization, hib3 recorded in Low income?
- The lowest recorded value was 0.0% in 1990.
- How does Low income rank for immunization, hib3?
- Low income ranks 38th out of 43 groups with data for 2024.
- Is immunization, hib3 rising or falling in Low income?
- Over the last ten years it is down 2.0%. The long-run trend across the full record is volatile.
- Where does this Low income data come from?
- The figures come from WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as part of Immunization, Hib3 (% of children ages 12-23 months). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 35 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.